MOTS-C in Tay Ho: Why Mitochondrial-Derived Peptides Are Attracting Research Interest

Key Takeaways

• MOTS-c belongs to a growing field of mitochondrial-derived peptides. These small peptides challenge the traditional view that mitochondrial DNA mainly matters through its 13 protein-coding genes involved in oxidative phosphorylation.
• Its biological origin is unusual. MOTS-c is associated with a short open reading frame within the mitochondrial 12S rRNA region and consists of 16 amino acids.
• Energy signaling is a central research theme. Studies have linked MOTS-c to folate and purine metabolism, AICAR-related signaling, and AMPK activation.
• Mitochondria-to-nucleus communication is another major focus. Under certain cellular stress conditions, MOTS-c has been observed to translocate to the nucleus and influence stress-response gene expression.
• Exercise research is promising but frequently overinterpreted. Findings involving endogenous MOTS-c and exercise do not prove that administering the isolated peptide reproduces the benefits of exercise.
• Most intervention evidence is preclinical. Cell and animal experiments provide mechanistic clues, not definitive evidence of human clinical benefit.
• Human intervention evidence is still developing. A registered phase 2 study of MOTS-c has been listed, but a registry entry is not proof of efficacy or safety.

1. What Are Mitochondrial-Derived Peptides?

Mitochondria are best known for their role in producing ATP, the molecule cells use to transfer energy for biological processes. They also contribute to nutrient metabolism, calcium regulation, cellular stress responses, and signaling networks that influence the nucleus.

For many years, the mitochondrial genome was understood primarily through its 13 protein-coding genes, which produce essential components of the oxidative phosphorylation system. Research into short open reading frames has expanded this picture. Some small genetic regions can encode biologically active peptides, now commonly called mitochondrial-derived peptides (MDPs).

Examples include humanin, the small humanin-like peptides (SHLPs), and MOTS-c. These peptides are being investigated as possible signaling molecules that connect mitochondrial biology with processes elsewhere in the cell or organism.

The significance is conceptual as well as practical. Mitochondria may not simply respond to signals from the nucleus; they may also communicate information about cellular energy status and stress back to nuclear gene-regulatory systems.

This field remains relatively young. The biological effects, molecular targets, tissue distribution, and physiological importance of individual mitochondrial-derived peptides differ, and findings about one peptide should not automatically be attributed to another.

2. What Is MOTS-c?

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. Lee and colleagues first described it in a 2015 study published in Cell Metabolism. The researchers identified a short open reading frame associated with the mitochondrial 12S rRNA region that encodes a 16-amino-acid peptide.

The original research connected MOTS-c with skeletal muscle metabolism, insulin sensitivity, and metabolic homeostasis. In experimental models, the peptide influenced pathways involving the folate cycle and de novo purine biosynthesis, with downstream effects associated with AMPK activation.

This discovery attracted attention because it suggested that a short peptide encoded by mitochondrial genetic material could influence whole-cell metabolic regulation. Rather than acting only as a structural component, MOTS-c appeared to participate in signaling between metabolic pathways.

It is important to distinguish the naturally occurring peptide studied in biological systems from synthetic products sold under the MOTS-c name. A product label alone does not demonstrate sequence identity, purity, stability, biological activity, or equivalence to the materials used in published experiments.

3. Why Mitochondrial Signaling Matters

3.1 Mitochondria are more than energy-producing organelles

Cells continuously adjust their activity in response to nutrient availability, oxygen levels, exercise, and other forms of stress. Mitochondria participate in this adaptation through changes in ATP production, reactive oxygen species (ROS), calcium signaling, and metabolic intermediates.

These signals can influence nuclear gene expression, allowing cells to adjust processes such as antioxidant defense, substrate utilization, and stress adaptation. This broader communication system is often described as mitochondrial retrograde signaling: information originating in or associated with mitochondria influences cellular responses elsewhere.

MOTS-c has attracted interest as a potential participant in this communication network. Experimental studies suggest that its effects may extend beyond mitochondrial energy production itself, involving metabolic pathways and stress-responsive nuclear gene expression.

3.2 Why researchers are studying short peptides

Small peptides can have biological functions even when they do not resemble conventional hormones or large proteins. A short peptide may interact with signaling proteins, alter metabolic pathways, or affect the activity of transcriptional regulators.

For mitochondrial-derived peptides, researchers are investigating whether these molecules provide a previously underappreciated layer of communication between mitochondrial and nuclear genomes. The existence of such signaling molecules could help explain how cells coordinate energy availability with other physiological demands.

However, identifying a peptide and observing a biological effect are only early stages of research. Scientists still need to establish the relevant molecular targets, physiological concentrations, tissue-specific functions, and importance of the peptide under normal human conditions.

4. MOTS-c and the AMPK Pathway

One of the most frequently discussed mechanisms in MOTS-c research involves AMP-activated protein kinase, or AMPK. AMPK is a cellular energy sensor that responds to changes in energy availability and helps coordinate metabolic adaptation.

4.1 What AMPK does

AMPK is a protein kinase that helps cells respond to energy stress. When activated, it can influence pathways involved in glucose uptake, fatty-acid metabolism, energy production, and the regulation of energy-consuming processes.

AMPK is relevant to exercise physiology because muscle contraction and changing energy demands can alter cellular energy signals. It is also studied in metabolic research because impaired energy regulation can be associated with insulin resistance and other metabolic disturbances.

AMPK is not a single-purpose fat-loss switch. Its effects depend on the tissue, physiological state, duration of activation, and interaction with other pathways. Evidence that a compound influences AMPK in a laboratory model does not automatically establish that it produces clinically meaningful weight loss or metabolic improvement in people.

4.2 The folate–purine–AICAR connection

In the original MOTS-c study, researchers reported effects on the folate cycle and the linked pathway of de novo purine biosynthesis. Changes in these processes were associated with increased levels of AICAR-related metabolites and activation of AMPK signaling.

AICAR is an intermediate associated with purine metabolism. Its phosphorylated form, ZMP, can act as an AMP mimetic and activate AMPK-related signaling. The reported relationship provides a mechanistic hypothesis for how MOTS-c may affect cellular energy regulation without acting as a conventional receptor agonist.

The pathway is scientifically interesting because it connects one-carbon metabolism and nucleotide biosynthesis with a broader cellular energy-sensing system. Nevertheless, it should not be presented as a fully resolved mechanism in every tissue or as proof that administering MOTS-c produces a predictable metabolic effect in humans.

4.3 How researchers test this pathway

Mechanistic studies may measure changes in metabolites, AMPK phosphorylation, glucose utilization, gene expression, or cellular responses after exposure to MOTS-c. Researchers may also inhibit a pathway or alter the expression of a relevant protein to test whether the observed effect depends on that component.

Such experiments can strengthen a causal explanation within the model being studied. Their limits include differences between cell systems and living organisms, uncertainty about human exposure, and the possibility that multiple pathways contribute to the same outcome.

5. MOTS-c and Mitochondria-to-Nucleus Communication

A second major research theme is the observation that MOTS-c can change its cellular location under certain stress conditions. Although it is associated with mitochondrial genetic material, experimental work has found MOTS-c in other cellular compartments and reported stress-related translocation into the nucleus.

5.1 Nuclear translocation under stress

In experimental systems, metabolic stressors such as nutrient restriction, serum deprivation, or oxidative stress have been associated with the movement of MOTS-c into the nucleus. Some studies suggest that this process is connected to AMPK-dependent signaling.

The observation raises an important question: could MOTS-c help cells adapt to changing metabolic conditions by influencing nuclear gene expression? Research has examined associations with stress-response transcription factors and genes involved in antioxidant defenses.

5.2 Antioxidant response elements and gene regulation

Published mechanistic research has linked nuclear MOTS-c activity with the regulation of genes containing antioxidant response elements (AREs). These DNA regulatory sequences are involved in cellular defense systems, including pathways associated with the transcription factor NRF2.

These findings offer a possible explanation for how mitochondrial-derived peptides could influence more than energy metabolism. If a peptide helps coordinate mitochondrial status with nuclear responses, it may participate in broader cellular adaptation.

However, the details of this signaling system remain under investigation. Researchers continue to examine which interactions are direct, how they vary across tissues, and how important the pathway is under normal physiological conditions in humans.

6. Why MOTS-c Is Attracting Interest in Exercise Research

Exercise places changing demands on skeletal muscle. Contracting muscles require energy, alter substrate utilization, and activate signaling pathways involved in adaptation. Researchers studying mitochondrial-derived peptides are interested in whether these molecules participate in the communication between muscular activity and systemic physiology.

A 2021 study published in Nature Communications reported that exercise induced endogenous MOTS-c expression in human skeletal muscle and circulation. In the same paper, administration experiments in mice investigated physical performance, skeletal muscle metabolism, and age-related changes in physical capacity.

The distinction between those findings is essential. The human component examined the body’s own MOTS-c response to exercise, while the intervention evidence concerning enhanced physical performance came from animal experiments. The human observations do not show that administering synthetic MOTS-c improves exercise capacity in people.

6.1 Exercise-responsive signaling

Exercise can influence AMPK, PGC-1α, and other signaling systems associated with energy regulation and muscle adaptation. MOTS-c has been investigated within this wider network because some experimental results suggest connections between its expression and metabolic stress responses.

PGC-1α is a transcriptional coactivator involved in mitochondrial biogenesis and metabolic adaptation. Its role in exercise-related physiology makes it a relevant pathway for studies exploring whether MOTS-c participates in longer-term changes in muscle function.

6.2 Why “exercise in a peptide” is an overstatement

Exercise produces many coordinated effects involving the cardiovascular system, nervous system, skeletal muscle, endocrine signals, and behavior. A single signaling molecule cannot be assumed to reproduce that complete response.

Even when an endogenous peptide increases during exercise, that association does not prove it is the main cause of the resulting physiological benefits. To demonstrate that a peptide reproduces or meaningfully contributes to those benefits, researchers would need appropriate intervention studies and carefully defined human outcomes.

7. MOTS-c, Insulin Sensitivity, and Metabolic Homeostasis

The original 2015 study helped establish MOTS-c as a metabolic research candidate. In cellular and animal experiments, the peptide was associated with changes in glucose utilization, insulin sensitivity, and metabolic homeostasis. Investigators also reported effects in mice exposed to high-fat diets and in models of age-related insulin resistance.

These findings matter because skeletal muscle is a major site of glucose disposal, and changes in muscle metabolism can influence whole-body glucose regulation. A molecule that affects muscle energy handling could therefore be relevant to research on insulin resistance.

But animal findings are not equivalent to clinical evidence. The dose, route of administration, exposure, metabolism, and physiological response in mice may differ substantially from those in humans. The relevant human effects, if any, must be established through well-designed clinical studies.

7.1 Why circulating MOTS-c measurements are difficult to interpret

Studies have examined endogenous MOTS-c concentrations in blood or tissue in relation to age, metabolic status, exercise, and disease. Results can vary by population, biological sample, assay, and study design.

A higher circulating concentration does not necessarily mean that a person is metabolically healthier. It could reflect a compensatory response, a difference in production or clearance, or another physiological factor. Likewise, a lower concentration does not independently establish a deficiency that should be corrected.

Biomarker studies can identify associations and help generate hypotheses, but they do not show that administering a peptide improves the condition associated with its measured concentration.

8. MOTS-c and Healthy Aging Research

Mitochondrial function and metabolic regulation are both areas of interest in aging research. Changes in mitochondrial activity, energy balance, and cellular stress responses have been associated with age-related physiological changes, making mitochondrial-derived peptides potential candidates for investigation.

Studies of MOTS-c have explored age-related insulin resistance, skeletal muscle function, physical performance, and stress adaptation. The animal findings reported by Reynolds and colleagues in 2021 added to interest in the peptide’s possible relationship with physical capacity across different ages in mice.

These results are hypothesis-generating rather than proof of an anti-aging treatment. Aging is a complex biological process involving multiple organ systems, and a change in one metabolic marker or animal performance measure cannot establish that a compound extends healthy human lifespan.

To evaluate an aging-related intervention, researchers would need to define the relevant outcomes, such as physical function, disease incidence, quality of life, or other validated measures. Claims about lifespan extension would require even more specific evidence and long-term observation.

9. What Does the Human Evidence Actually Show?

One of the most important distinctions in MOTS-c research is the difference between studying the peptide naturally produced by the body and administering MOTS-c as an investigational compound.

As of the evidence reviewed for this article, a phase 2 study of MOTS-c in adults with prediabetes and overweight or obesity has been registered under ClinicalTrials.gov identifier NCT07505745. The registry describes planned assessment of insulin sensitivity and treatment-emergent adverse events. No posted results were identified in the registry information reviewed here.

This is a meaningful development because it shows that direct human intervention research is being pursued. It does not establish that the study has demonstrated efficacy or that the peptide has a known, acceptable safety profile. Trial status and results should be rechecked as new information becomes available.

10. Research Statistics: What the Evidence Can Support

The central conclusion is not that MOTS-c has been shown to deliver all the benefits associated with its proposed pathways. Rather, a coherent set of biological hypotheses has emerged, and researchers are beginning to address the clinical questions required to evaluate those hypotheses in humans.

11. Safety, Product Quality, and the Limits of Current Knowledge

The biological interest in MOTS-c should not be confused with established clinical safety. The US Food and Drug Administration’s review of MOTS-c-related bulk drug substances has highlighted a lack of adequate human exposure information and uncertainty about potential safety risks. Important unanswered questions include immunogenicity, product characterization, and the clinical relevance of findings from nonclinical models.

For an investigational peptide, the absence of well-established human safety data is not evidence that the compound is safe. Nor does the absence of a known adverse event in a small or incomplete dataset establish that a risk does not exist.

Product identity and quality are additional concerns. Peptide sequence, purity, aggregation, stability, storage conditions, contaminants, and manufacturing consistency can all influence the material being studied. A commercial listing or certificate from a seller cannot independently establish that a product is equivalent to the substance used in a peer-reviewed experiment.

MOTS-c should therefore be approached as an investigational research compound rather than an established treatment for metabolic disease, athletic performance, or aging. Current regulatory information and peer-reviewed clinical evidence should take precedence over marketing claims.

12. What Researchers Still Need to Establish

• Pharmacokinetics: How an administered peptide is absorbed, distributed, metabolized, and eliminated in humans.
• Dose-response relationships: Whether measurable biological effects depend on exposure and how those relationships differ across tissues.
• Mechanism and target specificity: Which molecular interactions are direct and which occur through downstream metabolic changes.
• Human safety: Potential adverse effects, immunogenicity, tolerability, and longer-term risks.
• Clinical efficacy: Whether intervention produces meaningful changes in validated metabolic, functional, or other clinical outcomes.
• Population differences: Whether responses differ by age, metabolic status, sex, disease characteristics, or other relevant factors.
• Reproducibility: Whether independent studies confirm the findings across different laboratories, methods, and populations.

Answering these questions requires more than additional mechanistic papers. It requires appropriately designed studies, validated analytical methods, transparent reporting, and human data that can distinguish plausible biological activity from a clinically useful intervention.

13. Related Research Products and Educational Resources

Related Articles and Resources

• Vietnam Peptides Knowledge Hub — explore educational articles on peptide science, metabolism, and longevity research.
• Peptide Research FAQ — review general questions about research compounds and terminology.
• Peptide Products Overview — browse research product categories while distinguishing commercial listings from established clinical evidence.

14. Frequently Asked Questions

15. Scientific References

1. Lee C, Zeng J, Drew BG, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism. 2015;21(3):443–454. DOI: 10.1016/j.cmet.2015.02.009. PubMed.
2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. DOI: 10.1038/s41467-020-20790-0. PubMed.
3. Wan W, Zhang L, Lin Y, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine. 2023;21:36. DOI: 10.1186/s12967-023-03885-2. PubMed.
4. Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023;14:1120533. DOI: 10.3389/fendo.2023.1120533. Full text.
5. Mitochondrial-derived peptides and exercise. Biochimica et Biophysica Acta (BBA) – General Subjects. 2021. Review of exercise-responsive mitochondrial-derived peptides and their proposed roles in adaptation. Journal article.
6. ClinicalTrials.gov. NCT07505745: MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight or obesity. Registry record. ClinicalTrials.gov.
7. U.S. Food and Drug Administration. Clinical Studies Assessing Safety: MOTS-c-related bulk drug substances. FDA Pharmacy Compounding Advisory Committee materials. Official FDA document.
8. Kim SJ, Mehta HH, Wan J, et al. The Mitochondrial-Derived Peptide MOTS-c: A Promising Therapeutic Target in Metabolic and Age-Related Diseases. Foundational and follow-up MOTS-c research is summarized in the 2015 primary study and subsequent peer-reviewed reviews; interpretations should distinguish animal experiments from human clinical evidence. Open-access review at PubMed Central.

Conclusion

MOTS-c is attracting research interest because it connects several important questions in modern biology: how mitochondria communicate with the rest of the cell, how energy-sensing pathways respond to metabolic stress, and how these processes relate to exercise and age-associated physiological changes.

Preclinical findings involving AMPK, insulin sensitivity, stress-responsive gene expression, and physical performance provide a rationale for further investigation. Human studies of endogenous MOTS-c add physiological context, while registered intervention research represents an important step toward testing the peptide directly in people.

The evidence must still be interpreted carefully. A pathway observed in cells, a benefit measured in mice, and an association in human blood samples are not equivalent to a demonstrated clinical treatment effect. For MOTS-c, the next decisive questions concern human pharmacology, safety, and whether well-designed trials can establish meaningful clinical benefits.